Adaptive Biotechnologies Expands Executive Leadership Team to Support Development and Commercialization of Clinical Products, including immunoSEQ Dx
Adaptive Biotechnologies Corporation (ADPT)
Last adaptive biotechnologies corporation earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adhc.com
Company Research
Source: GlobeNewswire
SEATTLE, April 09, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the addition of two prominent hires to its executive leadership team. Mark Adams, Ph.D. has been appointed Chief Technical Officer to advance technology strategy across the company. Jyoti Palaniappan joins as Senior Vice President, Clinical Diagnostics, immunoSEQ Dx to establish the commercial infrastructure for the diagnostics pipeline resulting from our partnership with Microsoft. “We are excited to further expand our executive leadership team as we scale our organization and accelerate the development and commercialization of clinical products stemming from our immune medicine platform,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. “Mark’s experience leading large bioinformatics and data analytics pro
Show less
Read more
Impact Snapshot
Event Time:
ADPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADPT alerts
High impacting Adaptive Biotechnologies Corporation news events
Weekly update
A roundup of the hottest topics
ADPT
News
- Assessing Adaptive Biotechnologies (ADPT) Valuation After a 179% One-Year Rebound and Recent Pullback [Yahoo! Finance]Yahoo! Finance
- Adaptive Biotechnologies (NASDAQ:ADPT) was given a new $21.00 price target on by analysts at Morgan Stanley.MarketBeat
- Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual MeetingGlobeNewswire
- Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why [Yahoo! Finance]Yahoo! Finance
- Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3 [Yahoo! Finance]Yahoo! Finance
ADPT
Earnings
- 11/5/25 - Beat
ADPT
Sec Filings
- 12/4/25 - Form 144
- 12/4/25 - Form 144
- 12/3/25 - Form 144
- ADPT's page on the SEC website